USFDA Action on Granules India Does Not Affect Existing Products, but New Approvals May Be Impacted
Granules India Ltd, a leading pharmaceutical company, has responded to the recent action taken by the US Food and Drug Administration (USFDA). The company confirmed that the regulatory action does not impact its existing products already approved and in the market. However, the company acknowledged that the USFDA's action could potentially affect future approvals for new products. The company remains committed to complying with the regulatory guidelines and is actively working to address the concerns raised by the USFDA to avoid any disruptions to its product pipeline. Granules India reiterated its focus on quality and adherence to the highest standards of manufacturing practices to ensure the safety and efficacy of its pharmaceutical products. Despite the potential setbacks in new approvals, the company remains optimistic about its growth prospects and continues to focus on delivering high-quality generic medicines globally. Shares of Granules India saw some volatility following t...